Hematological Disorders



hemophilia chromosome mutation :: Article Creator

What To Know About Hemophilia A

Hemophilia A, also known as classic hemophilia or factor VIII deficiency, is a bleeding disorder. It occurs when certain proteins are missing in the blood, causing people to bleed and bruise easily.

Hemophilia refers to a group of inherited bleeding disorders in which the blood does not clot correctly. It typically occurs when people inherit gene variations that do not produce certain proteins, known as clotting factors. These proteins coagulate the blood and stop bleeding.

People with hemophilia may experience spontaneous bleeding or severe bleeding following injuries.

There are different types of hemophilia that affect different clotting proteins. Hemophilia A occurs when a person has a low level of clotting factor VIII. The less clotting factor a person has, the more likely it is that bleeding will occur.

In most cases, hemophilia is an inherited bleeding disorder. This means that a person inherits gene variations from their parents that affect their ability to produce blood clotting proteins.

Specifically, hemophilia A occurs due to a genetic alteration in the F8 gene, which is present on the X chromosome (one of two chromosomes that determine biological sex). This is why some health experts may refer to hemophilia A as an X-linked condition.

The F8 gene is responsible for producing clotting factor VIII, which is crucial for the blood clotting process. This gene variation results in insufficient levels of factor VIII, which leads to difficulty forming blood clots and causes prolonged bleeding.

Although a person typically inherits hemophilia A from a parent, evidence suggests that roughly 33% of cases occur in individuals with no family history of the condition.

In rare cases, a person may develop acquired hemophilia. This is when hemophilia develops in individuals without a personal or family history of conditions that affect blood clotting. It can occur if the body produces antibodies that mistakenly attack blood clotting factors.

However, in other cases, it may occur without a known cause. A 2021 article suggests that acquired hemophilia A is more complex than initially thought and may have many possible causes.

Hemophilia A is the most common type of hemophilia. However, there are different types of hemophilia. The characteristic feature of each type is the clotting factor they affect.

Hemophilia A occurs due to an alteration in the F8 gene, which causes a deficiency in clotting factor VIII.

Hemophilia B, also known as Christmas disease or factor IX deficiency, affects the F9 gene. As the name suggests, this type of hemophilia results in a low level of clotting factor IX. Hemophilia C, also known as factor XI deficiency, affects the F11 gene and causes a low level of clotting factor XI.

There are also less common conditions that affect other blood clotting factors.

The Centers for Disease Control and Prevention (CDC) note that hemophilia occurs in roughly 1 of every 5,000 male births. Approximately 400 males are born with hemophilia A each year. Hemophilia can also affect females, but this is much rarer.

The condition affects people from all racial and ethnic groups.

Most people with hemophilia A are born with it. In most cases, they inherit the condition from a parent. The genes for clotting factors, such as the F8 gene, are present on the X chromosome. A male will typically inherit one X chromosome from their female parent, while females will typically inherit an X chromosome from both their male and female parents.

This is why hemophilia A is more common in males, as they typically only require one gene variation to develop the condition. For hemophilia A to develop in females, they will either require two X chromosomes with a gene alteration or one variation and the other X chromosome to be missing or nonfunctional.

Read on to learn more about hemophilia inheritance patterns.

The characteristic feature of hemophilia A is a deficiency in the factor VIII clotting protein. The severity of symptoms will relate to the amount of clotting factor a person has in their blood. The symptoms of hemophilia A are typically as follows:

Severe hemophilia A

This typically describes a person with less than 1% clotting activity. Symptoms may include:

  • frequent and spontaneous joint and muscle bleeding
  • hemophilic arthropathy (irreversible joint damage), which can cause physical disability
  • prolonged bleeding or excessive pain and swelling after minor injuries or surgery
  • frequent nosebleeds
  • bruising easily
  • Moderate hemophilia A

    People with moderate hemophilia A typically have between 1–5% clotting factor activity. Symptoms may include:

  • occasional spontaneous bleeding
  • prolonged bleeding with more significant injuries or surgery
  • occasional nosebleeds
  • bruising easily
  • Mild hemophilia A

    Mild hemophilia A typically describes factor activity between 5–40%. Symptoms can include:

  • infrequent or no spontaneous bleeding
  • bleeding typically occuring only after injuries, trauma, or surgery
  • symptoms potentially not manifesting until later in life
  • In most cases, severe hemophilia A manifests in early life, while mild or moderate hemophilia A will present later in childhood or adolescence. As such, many people with hemophilia A may receive a diagnosis shortly after birth.

    Diagnosis of hemophilia A may involve blood tests to measure the levels and activity of clotting factors. These can include:

  • activated partial thromboplastin time
  • prothrombin time
  • fibrinogen level
  • platelet count
  • serum factor VIII activity
  • As well as providing a diagnosis, these tests can also help assess the severity of hemophilia A by identifying the amount of clotting factor a person has.

    Before giving birth, genetic testing and counseling can also help identify whether a person carries a gene variation and how likely it is to pass to children. Genetic testing can also determine the specific gene alteration responsible for the condition.

    Excessive bleeding due to hemophilia A can result in complications, especially if it is left untreated. These can include:

  • anemia from blood loss
  • bleeding in joints that can cause chronic joint disease, pain, and limited mobility
  • bleeding in the brain, which can cause long-term problems such as seizures and paralysis
  • bleeding in vital organs, which can be fatal
  • A person with hemophilia may also develop a type of antibody known as an inhibitor. These inhibitors can make it more difficult to treat a bleeding episode, as they can prevent treatments from working.

    Treatment for hemophilia A typically involves replacement therapy for the deficient factor VIII. This may involve regular infusions of factor VIII or antibody therapy.

    For cases of mild hemophilia A, a person may receive desmopressin for short-term support. This drug can help increase the concentration of factor VIII in the blood. A person may also receive aminocaproic acid or tranexamic acid oral medications to help treat bleeding.

    In June 2023, the Food and Drug Administration (FDA) gave approval for a gene therapy treatment for adults with severe hemophilia A. Roctavian uses a modified virus that contains the gene for factor VIII. After a single dose, the virus carries the factor VIII gene into liver cells, which enables the liver to produce factor VIII.

    Hemophilia A is a bleeding disorder that occurs due to a deficiency in clotting factor VIII. Most cases occur due to inheriting an alteration in the F8 gene.

    Hemophilia A can vary in severity and requires careful management to help prevent severe bleeding episodes and potential complications. Treatment often involves replacing the deficient factor VIII to help with blood clotting and help prevent excessive bleeding.


    The Evolving Market Dynamics Of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, And Von Willebrand DiseaseKey Analysis By DelveInsight

    Bleeding and clotting disorders are conditions that can impact both men and women, but women face unique issues related to these disorders because of the potential effects on their reproductive health and quality of life. Current data indicates that as many as 1% of women in the United States may be affected by a bleeding disorder, with many remaining unaware of their condition.

    LAS VEGAS, Oct. 9, 2023 /PRNewswire/ -- Bleeding disorders are typically hereditary, with common symptoms encompassing easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from minor cuts. Treatment approaches are tailored to the specific disorder and may involve factor replacement therapy, iron supplementation, topical applications, or blood transfusions.

    DelveInsight has recently released a series of epidemiology-based market reports focusing on factor-based bleeding disorders including Hemophilia A, Hemophilia B, and Von Willebrand Disease. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032  segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

    Additionally, the reports feature an examination of prominent companies working with their lead candidates in different stages of clinical development. Let's deep dive into the assessment of these factor-based bleeding disorders markets individually.

    Hemophilia A Market

    Hemophilia A is a hereditary bleeding disorder characterized by a deficiency or low levels of clotting factor VIII proteins in the bloodstream. Inadequate factor VIII inhibits proper blood clotting, leading to difficulty in controlling bleeding. While the disorder is typically inherited from parents, approximately one-third of cases occur without any prior family history. It results from an X-linked recessive genetic trait, with the malfunctioning gene located on the X chromosome. In females, who possess two X chromosomes, the unaffected gene on the other chromosome can compensate for the defective one, ensuring sufficient factor VIII production. According to DelveInsight's recently published Hemophilia A market report, the total prevalent population of Hemophilia A in the 7MM comprised of 45K cases in 2021 and are projected to increase by 2032.

    Approximately 30% of severe Hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which make FVIII replacement therapy ineffective. The standard treatment approach for patients with inhibitors involves inducing immune tolerance with high-dose, high-frequency FVIII and using bypassing agents, such as recombinant activated factor VII (e.G., NOVOSEVEN) or FEIBA. Hemophilia A management includes various approved therapies, such as HEMLIBRA (for both inhibitor and non-inhibitor cases), SEVENFACT, KOGENATE FS, FEIBA, KOVALTRY, ELOCTATE, NUWIQ, AFSTYLA, and others. 

    Recently in February 2023, the US FDA approved ALTUVIIIO (efanesoctocog alfa) factor VIII replacement therapy for adults and children with hemophilia A. ALTUVIIIO is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with hemophilia A. Last year in September 2022, the company filed for approval in Japan. In August 2022, EC granted conditional marketing authorization to Roctavian gene therapy for treating severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VII inhibitors and without detectable antibodies to adeno-associated virus serotype 5. Whereas, in June 2023, BioMarin made a significant announcement revealing the FDA's approval of Roctavian as a one-time remedy for individuals suffering from severe hemophilia A. 

    Learn more about the FDA-approved drugs for hemophilia A @ Drugs for Hemophilia A Treatment

    DelveInsight estimated that the hemophilia A market size is projected to grow from USD 8.5 billion in 2021 at a significant CAGR BY 2032. Currently, the treatment hemisphere is mainly driven by non-inhibitor drug candidates. Emerging potential candidates pose an adverse threat to current hemophilia A pharmaceuticals giants, by means of their potential to transform the standard of care for hemophilia A patients. The hemophilia treatment landscape continues to evolve, and several companies are furiously working toward the development of new treatments that could potentially cure and change the treatment landscape of hemophilia A. Companies are focused on the development of gene therapies that bispecific antibodies for the treatment of hemophilia A, this shall create a positive impact on the hemophilia A market size in coming years.

    Hemophilia A Pipeline Therapies and Key Companies

  • RG6357 (SPK-8011): Roche (Spark Therapeutics)
  • RG6358 (SPK-8016): Roche (Spark Therapeutics)
  • SerpinPC: ApcinteX
  • Concizumab (NN7415): Novo Nordisk
  • Fitusiran (ALN-AT3, SAR-439774): Sanofi (Genzyme)/Alnylam Pharmaceuticals
  • BIVV001 (Efanesoctocog alfa) (rFVIIIFc-VWF-XTEN): Sanofi
  • Marstacimab (PF-06741086): Pfizer
  • NNC0365-3769 A (Mim8): Novo Nordisk A/S
  • Giroctocogene fitelparvovec (SB-525 or PF-07055480): Pfizer/Sangamo Therapeutics
  • BAY2599023 (DTX201 AAV FVIII): Bayer/Ultragenyx Pharmaceutical
  • Dive deeper for rich insights into the Hemophilia A Clinical Trials

    Hemophilia B Market

    Hemophilia B, a rare genetic bleeding disorder, is characterized by a deficiency of a blood protein known as factor IX. The level of factor IX in an affected individual's blood dictates the severity of their hemophilia. Approximately 3 out of every 100 people with hemophilia B develop an antibody, referred to as an inhibitor, against the factor IX replacement therapy utilized to manage or prevent bleeding episodes. This inhibitor impedes the effectiveness of the therapy, making it more challenging to prevent episodes of bleeding. As per DelveInsight's analysis, in 2022, the total treated prevalent population of hemophilia B in the US was approximately 4K. As per the estimates it can be observed that moderate hemophilia B cases are higher in number than mild and severe cases in the US.

    At present, there is no known cure for hemophilia, but researchers are actively dedicated to developing a cure through gene therapy. One promising approach involves introducing a healthy version of the faulty blood factor gene, allowing individuals with hemophilia to produce adequate levels of the factor themselves. Treatment for hemophilia B typically includes two main approaches: "On-Demand and "Prophylaxis." In recent years, the importance of prophylaxis treatment has been increasingly recognized over on-demand options. The primary treatment options for hemophilia B currently include Recombinant Factor IX Concentrates, Plasma-Derived Factor IX Concentrates, and Fresh Frozen Plasma.

    In November 2022, the US FDA approved HEMGENIX (etranacogene dezaparvovec) developed by uniQure Pharmaceuticals. It is an adeno-associated virus vector-based gene therapy to treat adults with hemophilia B (congenital Factor IX deficiency) who currently use factor IX prophylaxis therapy or have a current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes.

    As per DelveInsight analysis, in 2022, the total hemophilia B market size in the 7MM was approximately USD 3.2 billion. HEMGENIX and fidanacogene elaparvovec work by delivering a functional copy of the defective gene coding for factor IX. There is tough competition between these two gene therapies as both aim to provide a cure for hemophilia B by addressing the underlying genetic defect. HEMGENIX is already approved in the US in 2023 whereas the FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for fidanacogene elaparvovec in the second quarter of 2024. In the US and Japan, hemophilia B patients have shifted to Extended Half-Life (EHL) recombinant FIX treatment options compared to EU4 and the UK. Latest data from Europe suggests that still more than 50% of patients are receiving the recombinant FIX options with Standard Half-life (SHL).

    The dynamics of the hemophilia B therapeutic market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with hemophilia B.

    Hemophilia B Pipeline Therapies and Key Companies

  • Marstacimab (PF-06741086): Pfizer
  • Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
  • Fitusiran (ALN-AT3, SAR-439774): Sanofi (Genzyme)/Alnylam Pharmaceuticals
  • Concizumab (NN-7415): Novo Nordisk
  • Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics
  • SerpinPC (AP-0101): ApcinteX
  • For a comprehensive view of the hemophilia B market, check out the Hemophilia B Market Assessment

    Von Willebrand Disease Market

    Von Willebrand disease is the most prevalent hereditary bleeding disorder in the United States, impacting an estimated 1 in every 1,000 individuals. The unfortunate reality is that there is a substantial dearth of awareness within the patient community, their close-knit families, healthcare professionals, and the wider community, leading to detrimental effects on patients' health and their overall quality of life. Von Willebrand disease is frequently likened to hemophilia, though it presents distinct characteristics and bleeding tendencies. It has an equal incidence in both males and females, unlike hemophilia, which predominantly affects males. A parent carrying the VWD gene has a 50% likelihood of transmitting it to their offspring. As per DelveInsight estimates, the total diagnosed von Willebrand disease prevalence was 12.5K in the US in 2020, which is further expected to increase with a significant CAGR by 2032.

    The current approach to treating Von Willebrand disease in the United States encompasses three primary categories of drugs: Non-replacement Therapy, which involves the use of desmopressin (DDAVP) to boost vWF levels in the bloodstream; Replacement Therapy, utilizing plasma-derived coagulation factor concentrates such as Humate-P, Alphanate, Immunate, and Wilate; and Adjunct Therapy, primarily employing antifibrinolytics like Tranexamic Acid (Cyclokapron). 

    In the realm of recombinant coagulation factor concentrates, a novel addition, Vonvendi by Shire, has recently emerged in the field of replacement therapy. Market contributors, including approved (along with their generic counterparts) and off-label products used in the treatment of von Willebrand disease, predominantly fall within these therapeutic categories. For non-replacement therapy options, Desmopressin has traditionally served as the primary treatment choice, particularly for patients with Type 1 variants and select type 2 cases. Notable medications in this category, all featuring desmopressin acetate as the active ingredient, encompass Stimate (CSL Behring GmbH), DDAVP (Sanofi-Aventis), and Octostim (CSL Behring GmbH).

    DelveInsight's analysts estimate that the von Willebrand disease market is expected to show positive growth and will grow from USD 309 million in 2020 at a significant CAGR by 2032. The dynamics of the von Willebrand disease market are anticipated to change in the coming years owing to the expanded use of Vonvendi (BAX 111) for prophylactic as well as pediatric therapies in the US. Its expanded approval is also expected to raise awareness among a large section of von Willebrand disease patients who have VWF defects and have moderate disease but are currently undertreated. Overall, the increasing diagnosed prevalence of the disease along with the promising expanded recombinant therapies will fuel the von Willebrand disease market during the forecasted period of 2023–2032.

    Von Willebrand Disease Pipeline Therapies and Key Companies

  • Emicizumab: Genentech, Inc.
  • Wilate: Octapharma
  • rVWF: Takeda
  • For a deeper understanding of the VMD market landscape, explore the Von Willebrand Disease Market Outlook

    Trending Hematological Disorders Reports

    Multiple Myeloma Market

    Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, among others.

    Sickle Cell Disease Market

    Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sickle cell disease companies, including Vertex Pharmaceuticals, CRISPR Therapeutics, Bluebird Bio, Global Blood Therapeutics, Pfizer, among others.

    Beta-Thalassemia Market

    Beta-Thalassemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key beta-thalassemia companies, including Novartis, Merck, Bristol Myers Squibb, Chiesi Farmaceutici S.P.A, Bluebird Bio, Agios Pharmaceuticals, Imara Inc., CRISPR Therapeutics, Vertex Pharmaceuticals, Vifor Pharma, Ionis Pharmaceuticals, Forma Therapeutics, DisperSol Technologies, SILENCE Therapeutics, among others.

    Warm Autoimmune Hemolytic Anemia Market

    Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key wAIHA companies, including Zenas BioPharma, Sanofi, Johnson & Johnson, Novartis Pharmaceuticals, Incyte Corporation, Rigel Pharmaceuticals, Alpine Immune Sciences, Inc., Hutchison Medipharma Limited, among others.

    About DelveInsight

    DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

    Contact UsShruti Thakurinfo@delveinsight.Com +1(919)321-6187www.Delveinsight.Com  

    Logo: https://mma.Prnewswire.Com/media/1082265/3528414/DelveInsight_Logo.Jpg

     

    SOURCE DelveInsight Business Research, LLP

    © 2023 Benzinga.Com. Benzinga does not provide investment advice. All rights reserved.


    Small But Mighty New Gene Editor

    A new CRISPR-based gene-editing tool has been developed which could lead to better treatments for patients with genetic disorders. The tool is an enzyme, AsCas12f, which has been modified to offer the same effectiveness but at one-third the size of the Cas9 enzyme commonly used for gene editing. The compact size means that more of it can be packed into carrier viruses and delivered into living cells, making it more efficient. Researchers created a library of possible AsCas12f mutations and then combined selected ones to engineer an AsCas12f enzyme with 10 times more editing ability than the original unmutated type. This engineered AsCas12f has already been successfully tested in mice and has the potential to be used for new, more effective treatments for patients in the future.

    By now you have probably heard of CRISPR, the gene-editing tool which enables researchers to replace and alter segments of DNA. Like genetic tailors, scientists have been experimenting with "snipping away" the genes that make mosquitoes malaria carriers, altering food crops to be more nutritious and delicious, and in recent years begun human trials to overcome some of the most challenging diseases and genetic disorders. The potential of CRISPR to improve our lives is so phenomenal that in 2020, researchers Jennifer Doudna and Emmanuelle Charpentier, who developed the most precise version of the tool named CRISPR-Cas9, were awarded the Nobel Prize in chemistry.

    But even Cas9 has limitations. The common way to deliver genetic material into a host cell is to use a modified virus as a carrier. Adeno-associated viruses (AAVs) are not harmful to patients, can enter many different types of cells to introduce CRISPR enzymes like Cas9, and have a lower likelihood of provoking an undesired immune response compared to some other methods. However, like any parcel delivery service, there is a size limit. "Cas9 is at the very limit of this size restriction, so there has been a demand for a smaller Cas protein that can be efficiently packaged into AAV and serve as a genome-editing tool," explained Professor Osamu Nureki from the Department of Biological Sciences at the University of Tokyo.

    Its large size means that Cas9 can lack efficiency when used for gene therapy. So, a large multi-institutional team worked to develop a smaller Cas enzyme that is just as active, but more efficient. The researchers selected an enzyme called AsCas12f, from the bacteria Axidibacillus sulfuroxidans. The advantage of this enzyme is that it is one of the most compact Cas enzymes found to date and less than one-third the size of Cas9. However, in previous tests it showed barely any genome activity in human cells.

    "Using a screening method called deep mutational scanning, we assembled a library of potential new candidates by substituting each amino acid residue of AsCas12f with all 20 types of amino acids on which all life is based. From this, we identified over 200 mutations that enhanced genome-editing activity," explained Nureki. "Based on insights gained from the structural analysis of AsCas12f, we selected and combined these enhanced-activity amino acid mutations to create a modified AsCas12f. This engineered AsCas12f has more than 10 times the genome-editing activity compared to the usual AsCas12f type and is comparable to Cas9, while maintaining a much smaller size."

    The team has already carried out animal trials with the engineered AsCas12f system, partnering it with other genes and administering it to live mice. Administering treatments directly into the body is preferable to extracting cells, editing them in a lab and reinserting them into patients, which is more time-intensive and costly. The success of the tests showed that engineered AsCas12f has the potential to be used for human gene therapies, such as treating hemophilia, a disease in which the blood does not clot normally.

    The team discovered numerous potentially effective combinations for engineering an improved AsCas12f gene-editing system, so the researchers acknowledge the possibility that the selected mutations may not have been the most optimal of all the available mixes. As a next step, computational modeling or machine learning could be used to sift through the combinations and predict which might offer even better improvements.






    Comments